Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

Bone

Volumn 47, Issue 3, 2010, Pages 493-502

  Miyauchi, Akimitsu ^a   Matsumoto, Toshio ^b   Sugimoto, Toshitsugu ^c   Tsujimoto, Mika ^a   Warner, Margaret R ^a   Nakamura, Toshitaka ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Bone mineral density; Bone turnover markers; Fracture; Placebo controlled study; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ABDOMINAL PAIN; AGED; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAPHYLAXIS; ARTERY DISSECTION; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BODY MASS; BONE DENSITY; BONE TURNOVER; BRACHIAL PLEXUS INJURY; BREAST CANCER; BRONCHITIS; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CATARACT; CELLULITIS; CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL; COLON POLYP; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CYSTITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; FALLING; FEMALE; FEMUR NECK; FEMUR NECK FRACTURE; FRACTURE; FRAGILITY FRACTURE; HERPES ZOSTER; HIP; HUMAN; HUMERUS FRACTURE; HYPOTENSION; INTESTINE OBSTRUCTION; ISCHEMIC COLITIS; JAPANESE; JOINT DISLOCATION; LEG CRAMP; LUMBAR SPINE; LUNG ADENOCARCINOMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; OSSIFICATION; OSTEOARTHRITIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSITIONAL VERTIGO; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SHOULDER IMPINGEMENT SYNDROME; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UROLITHIASIS; VITAMIN SUPPLEMENTATION; VOMITING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; TERIPARATIDE;

EID: 77955846573     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.022     Document Type: Article

References (20)

1. Sakai A., Sakata T., Ikeda S., Uchida S., Okazaki R., Norimura T., et al. Intermittent administration of human parathyroid hormone(1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J Bone Miner Res 1999, 14:1691-1699.
2. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278:50259-50272.
3. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
4. Boonen S., Marin F., Mellstrom D., Xie L., Desaiah D., Krege J.H., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006, 54:782-789.
5. McClung M.R., San M.J., Miller P.D., Civitelli R., Bandeira F., Omizo M., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005, 165:1762-1768.
6. Miyauchi A., Matsumoto T., Shigeta H., Tsujimoto M., Thiebaud D., Nakamura T. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 2008, 26:624-634.
7. Orimo H., Sugioka Y., Fukunaga M., Muto Y., Hotokebuchi T., Gorai I., et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998, 16:139-150.
8. Lu Y., Mathur A.K., Blunt B.A., Gluer C.C., Will A.S., Fuerst T.P., et al. Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 1996, 11:626-637.
9. Orimo H., Hayashi Y., Fukunaga M., Sone T., Fujiwara S., Shiraki M., et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001, 19:331-337.
10. Genant H.K., Wu C.Y., van K.C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.
11. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., Hadji P., Farrerons J., Boonen S., et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008, 23:1591-1600.
12. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006, 22:61-66.
13. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
14. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
15. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
16. Iki M., Akiba T., Matsumoto T., Nishino H., Kagamimori S., Kagawa Y., et al. Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 2004, 15:981-991.
17. Nevitt M.C., Chen P., Dore R.K., Reginster J.Y., Kiel D.P., Zanchetta J.R., et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273-280.
18. Nevitt M.C., Chen P., Kiel D.P., Reginster J.Y., Dore R.K., Zanchetta J.R., et al. Reduction in the risk of developing back pain persists at least 30months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:1630-1637.
19. Hwang J.S., Tu S.T., Yang T.S., Chen J.F., Wang C.J., Tsai K.S. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006, 17:373-378.
20. Kung A.W., Pasion E.G., Sofiyan M., Lau E.M., Tay B.K., Lam K.S., et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006, 22:929-937.